Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2012 by AB Science.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
AB Science Identifier:
First received: October 25, 2011
Last updated: December 12, 2012
Last verified: December 2012
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)